UDCA's Role in Reducing Heart Fibrosis
Author Information
Author(s): Reilly-O’Donnell B., Ferraro E., Tikhomirov R., Nunez-Toldra R., Shchendrygina A., Patel L., Wu Y., Mitchell A. L., Endo A., Adorini L., Chowdhury R. A., Srivastava P. K., Ng F. S., Terracciano C., Williamson C., Gorelik J.
Primary Institution: National Heart and Lung Institute, Imperial College London
Hypothesis
Does ursodeoxycholic acid (UDCA) have an antifibrotic effect in cardiac fibrosis mediated by TGR5 signaling?
Conclusion
UDCA effectively reduces markers of cardiac fibrosis in both human and rat models, primarily through TGR5 signaling.
Supporting Evidence
- UDCA reduced myofibroblast markers in rat and human fibroblasts.
- UDCA reversed the profibrotic IL-11 and TGFβ/WWP2 gene networks.
- TGR5 was identified as the most highly expressed UDCA receptor in cardiac fibroblasts.
- UDCA is well tolerated in the treatment of other diseases, indicating it is a good candidate for further trials.
Takeaway
UDCA is a medicine that can help make hearts healthier by stopping the bad stuff that makes them stiff and weak.
Methodology
The study used cellular models, living myocardial slices, and RNA-seq to analyze the effects of UDCA on cardiac fibrosis.
Potential Biases
Potential bias due to the use of specific animal models and human samples.
Limitations
The study primarily focused on specific cell types and may not fully represent all aspects of cardiac fibrosis.
Participant Demographics
Human samples were taken from patients with dilated cardiomyopathy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website